Pancreatic Cancer Trial, Recruiting NCT05296421 Sponsor: Rutgers, The State University of New Jersey Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05296421
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma), confirmed by a biopsy, and your doctors believe surgery to remove the cancer may be possible
  • You are willing to have small tissue samples (biopsies) taken from your tumor and nearby normal tissue during your surgery for research purposes
  • You either have not received any prior treatment for this cancer, OR you have received at least 3 months of chemotherapy before surgery (the trial is looking for 8 people in each group)
  • You are able to understand what the study involves and are willing to sign a consent form before joining

Who may not be able to join:

  • You are in the "no prior treatment" group but have already received anti-cancer treatment such as chemotherapy, immunotherapy, or biologic therapy
  • You are in the "prior treatment" group but have received radiation therapy, biologic therapy, or immunotherapy before surgery (chemotherapy only is allowed for this group)
  • You are currently taking part in, or planning to join, another clinical trial that involves experimental treatments at the same time as this study
  • You currently have another active cancer
  • You are able to become pregnant and have not recently had a negative pregnancy test done as part of your standard cancer care (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Howard S Hochster, MD, Rutgers Cancer Institute of New Jersey

Phone: 732-235-5912

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Rutgers, The State University of New Jersey
Registry
ClinicalTrials.gov
Start date
14 March 2022
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To measure glycolysis metabolism dependencies via liquid chromatography-mass spectrometry (LC-MS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov